Literature DB >> 2860618

Reinnervation of dopamine-denervated striatum by substantia nigra transplants: immunohistochemical and electrophysiological correlates.

I Strömberg, S Johnson, B Hoffer, L Olson.   

Abstract

This study evaluated whether or not fetal substantia nigra tissue, grafted to striatum previously lesioned with 6-hydroxydopamine, provides functional dopaminergic reinnervation of striatum. Falck-Hillarp histochemistry and immunofluorescent staining for tyrosine hydroxylase demonstrated extensive networks of nerve fibers which extended 1-1.5 mm from the nigral grafts into striatal tissue. Multibarrel micropipettes were used to record neurons electrophysiologically and test neuronal responses to phencyclidine which was applied locally by pressure microejection. "Distal" neurons, defined as those striatal neurons more than 2.0 mm from the nigral graft, fired at an average spontaneous rate of 13.4 spikes/s and were relatively insensitive to the effects of locally applied phencyclidine. However, "proximal" neurons, defined as those neurons less than 1.0 mm from nigral grafts, fired at a significantly lower average rate of 4.9 spikes/s, and were significantly more sensitive than distal neurons to the effects of phencyclidine. These results suggest that fetal substantia nigra grafts can provide functionally significant reinnervation of striatum previously lesioned with 6-hydroxydopamine.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2860618     DOI: 10.1016/0306-4522(85)90270-2

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  12 in total

Review 1.  Transplantation into the human brain: present status and future possibilities.

Authors:  O Lindvall
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-06       Impact factor: 10.154

Review 2.  Transplantation of embryonic dopamine neurons: what we know from rats.

Authors:  S B Dunnett
Journal:  J Neurol       Date:  1991-04       Impact factor: 4.849

3.  Intrastriatal mesencephalic grafts affect neuronal activity in basal ganglia nuclei and their target structures in a rat model of Parkinson's disease.

Authors:  N Nakao; M Ogura; K Nakai; T Itakura
Journal:  J Neurosci       Date:  1998-03-01       Impact factor: 6.167

4.  Glial cell line-derived neurotrophic factor is essential for postnatal survival of midbrain dopamine neurons.

Authors:  A C Granholm; M Reyland; D Albeck; L Sanders; G Gerhardt; G Hoernig; L Shen; H Westphal; B Hoffer
Journal:  J Neurosci       Date:  2000-05-01       Impact factor: 6.167

5.  Intracerebral xenografts of human mesencephalic tissue into athymic rats: immunochemical and in vivo electrochemical studies.

Authors:  I Strömberg; P Almqvist; M Bygdeman; T E Finger; G Gerhardt; A C Granholm; T J Mahalik; A Seiger; B Hoffer; L Olson
Journal:  Proc Natl Acad Sci U S A       Date:  1988-11       Impact factor: 11.205

6.  Brain transplantation--still fantasy? Discussion paper.

Authors:  K E Morrison
Journal:  J R Soc Med       Date:  1987-07       Impact factor: 5.344

7.  Enhanced survival of dopaminergic neuronal transplants in hemiparkinsonian rats by the p53 inactivator PFT-α.

Authors:  J Chou; N H Greig; D Reiner; B J Hoffer; Y Wang
Journal:  Cell Transplant       Date:  2011-02-03       Impact factor: 4.064

8.  Neural grafting to ischemic lesions of the adult rat hippocampus.

Authors:  N Tønder; T Sørensen; J Zimmer; M B Jørgensen; F F Johansen; N H Diemer
Journal:  Exp Brain Res       Date:  1989       Impact factor: 1.972

9.  Human fetal dopamine neurons grafted in a rat model of Parkinson's disease: ultrastructural evidence for synapse formation using tyrosine hydroxylase immunocytochemistry.

Authors:  D J Clarke; P Brundin; R E Strecker; O G Nilsson; A Björklund; O Lindvall
Journal:  Exp Brain Res       Date:  1988       Impact factor: 1.972

10.  Transplantation of ventral mesencephalic anlagen to hosts with genetic nigrostriatal dopamine deficiency.

Authors:  L C Triarhou; W C Low; B Ghetti
Journal:  Proc Natl Acad Sci U S A       Date:  1986-11       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.